LTR Pharma (ASX:LTP) Change In Receivables: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:LTP LTR Pharma Ltd ASX:LTP
7 GF Score
Price A$0.51
View Full Analysis

What is LTR Pharma Change In Receivables?

LTR Pharma ASX:LTP +3.03% 7 Change In Receivables is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 7/100.

LTR Pharma's change in receivables for the quarter that ended in Dec. 2025 was A$0.00 Mil. It means LTR Pharma's Accounts Receivable stayed the same from Jun. 2025 to Dec. 2025 .

LTR Pharma's change in receivables for the fiscal year that ended in Jun. 2025 was A$0.00 Mil. It means LTR Pharma's Accounts Receivable stayed the same from Jun. 2024 to Jun. 2025 .

LTR Pharma's Accounts Receivable for the quarter that ended in Dec. 2025 was A$0.51 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. LTR Pharma's Days Sales Outstanding for the six months ended in Dec. 2025 was 1,250.37.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. LTR Pharma's liquidation value for the six months ended in Dec. 2025 was A$25.71 Mil.

LTR Pharma  (ASX:LTP) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

LTR Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.507/0.074*91
=1,250.37

2. In Ben Graham's calculation of liquidation value, LTR Pharma's accounts receivable are only considered to be worth 75% of book value:

LTR Pharma's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=25.781-0.458+0.75 * 0.507+0.5 * 0.02
=25.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Change In Receivables Related Terms

LTR Pharma Change In Receivables Historical Data

* Premium members only.

The historical data trend for LTR Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Change In Receivables Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Change In Receivables
0.00 0.00 0.00 0.00 0.00

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Receivables Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ASX:LTP
7GF Score
LTR Pharma Ltd ASX:LTP
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of A$0.00 Mil mean?
LTR Pharma (ASX:LTP) has a Change In Receivables of A$0.00 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for LTR Pharma and its competitors.
Is LTR Pharma's Change In Receivables too high?
LTR Pharma's current Change In Receivables is A$0.00 Mil. Overall, LTR Pharma has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Change In Receivables compare to VRTX and REGN?
LTR Pharma's Change In Receivables of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for LTR Pharma and its competitors. LTR Pharma's current Change In Receivables is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Change In Receivables of A$0.00 Mil. The current Change In Receivables is A$0.00 Mil. LTR Pharma's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Change In Receivables is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
7GF Score

Get the complete analysis for ASX:LTP

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.51
Price